Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Creative Commons License

Yozgat A. K., LEBLEBİSATAN G., AKBAYRAM S., Ozel S. C., Karakas Z., ERDURAN E., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.3, ss.139-144, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4274/tjh.galenos.2020.2019.0380
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.139-144
  • Anahtar Kelimeler: Immune thrombocytopenia, Eltrombopag, Iron deficiency, QUALITY-OF-LIFE, DOUBLE-BLIND, THROMBOPOIETIN, ROMIPLOSTIM, ADULTS
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.